×
Terumo Cash on Hand 2012-2024 | TRUMY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Terumo cash on hand for the quarter ending June 30, 2024 was
$1.259B
, a
36.21% decline
year-over-year.
Terumo cash on hand for 2024 was
$1.594B
, a
14.94% increase
from 2023.
Terumo cash on hand for 2023 was
$1.387B
, a
24.1% decline
from 2022.
Terumo cash on hand for 2022 was
$1.827B
, a
3.71% decline
from 2021.
View More
Terumo Cash on Hand 2012-2024 | TRUMY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Terumo cash on hand for 2024 was
$1.594B
, a
14.94% increase
from 2023.
Terumo cash on hand for 2023 was
$1.387B
, a
24.1% decline
from 2022.
Terumo cash on hand for 2022 was
$1.827B
, a
3.71% decline
from 2021.
Related Stocks
Company Name
Market
Cap
Abbott Laboratories (ABT)
$205.5B
Stryker (SYK)
$138.7B
Boston Scientific (BSX)
$121.5B
Medtronic (MDT)
$113.7B
EssilorLuxottica (ESLOY)
$104.2B
Haleon (HLN)
$48.6B
Lonza Group Ag (LZAGY)
$45.9B
ResMed (RMD)
$36.9B
Koninklijke Philips (PHG)
$29.3B
Zimmer Biomet Holdings (ZBH)
$21.6B
Baxter (BAX)
$20.3B
Insulet (PODD)
$16.5B
Smith & Nephew SNATS (SNN)
$13.5B
Bio-Rad Laboratories (BIO)
$9.3B
Demant (WILYY)
$9.2B
BellRing Brands (BRBR)
$7.7B
Lantheus Holdings (LNTH)
$7.3B
ICU Medical (ICUI)
$4.3B
Haemonetics (HAE)
$3.9B
TG Therapeutics (TGTX)
$3.9B
GN Store Nord (GNNDY)
$3.8B
Perrigo (PRGO)
$3.8B
Neogen (NEOG)
$3.7B
Prestige Consumer Healthcare (PBH)
$3.6B
Envista Holdings (NVST)
$3.3B
QuidelOrtho (QDEL)
$3.1B
Agios Pharmaceuticals (AGIO)
$2.6B
Maravai LifeSciences Holdings (MRVI)
$2.3B
Green Thumb Industries (GTBIF)
$2.2B
LeMaitre Vascular (LMAT)
$2B